AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BOTANIX PHARMACEUTICALS LTD

0.395

+0.0102.60%

Volume:5.38M

Turnover:2.10M

Market Cap:723.93M

PE:-17.00

High:0.400

Open:0.390

Low:0.375

Close:0.385

Loading ...

Overview Company News Filings

ASX Midday Sector Update: Healthcare Sector Jumps, Information Technology Stocks Struggle

MT Newswires Live

Botanix Pharmaceuticals Seeks AU$40 Million via Institutional Placement; Shares Rise 10%

MT Newswires Live

BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million

Botanix Pharmaceuticals - Received Firm Commitments for a$40 Mln Capital Raising at Issue Price of a$0.33 per Share

THOMSON REUTERS

Botanix Pharmaceuticals Ltd-Proposed Issue of Securities - BOT

THOMSON REUTERS

BRIEF-Botanix Pharmaceuticals Seeks Trading Halt

3 reasons to buy this surging ASX All Ords healthcare share today

ASX Growth Stocks With High Insider Ownership That Stand Out

Simply Wall St.

ASX Market Close: Index pares losses as US recession fears rise | March 11, 2025

The Market Herald

BRIEF-Botanix Pharmaceuticals Announces Commercial Launch Of SOFDRA

Botanix Pharmaceuticals Says Commercial Launch of Lead Dermatology Product 'On Track'

MT Newswires Live

Botanix Pharmaceuticals Ltd - Announces Commercial Launch of Sofdra

THOMSON REUTERS

Analysts Are Optimistic We'll See A Profit From Botanix Pharmaceuticals Limited (ASX:BOT)

Simply Wall St.

Botanix Pharmaceuticals Stock Sell-Off Has 'No Good Reasons,' Says Euroz Hartleys

MT Newswires Live

Botanix Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Revenue

MT Newswires Live

BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$30.9 Mln

Analysts Are Optimistic We'll See A Profit From Botanix Pharmaceuticals Limited (ASX:BOT)

Simply Wall St.

Sales Traction from Botanix Pharmaceuticals' Prescription Gel Launch May Drive Stock Re-rating, Euroz Hartleys Says

MT Newswires Live

Botanix Pharmaceuticals' Prescription Gel Commercial Launch Could Drive Stock Re-rating, Euroz Hartleys Says

MT Newswires Live

5 ASX All Ords shares starting the new year at 52-week highs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BOT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.395,"timestamp":1744870320000,"preClose":0.385,"halted":0,"volume":5382654,"delay":0,"nameEN":"BOTANIX PHARMACEUTICALS LTD","floatShares":1589206761,"shares":1832728341,"eps":-0.023239,"marketStatus":"Closed Easter Monday","change":0.01,"latestTime":"04-17 16:12:00 AEST","open":0.39,"high":0.4,"low":0.375,"amount":2104364,"amplitude":0.064935,"askPrice":0.405,"askSize":31304,"bidPrice":0.39,"bidSize":202960,"shortable":3,"etf":0,"ttmEps":-0.023239,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.385,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.6092759240532699,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1589206761,"roa":"-34.36%","roe":"-56.99%","lyrEps":-0.009236,"volumeRatio":0.6092759240532699,"shares":1832728341,"dividePrice":0,"high":0.4,"amplitude":0.064935,"preClose":0.385,"low":0.375,"week52Low":0.21,"pbRate":"7.83","psRate":"349.87","week52High":0.535,"institutionHeld":0,"latestPrice":0.395,"committee":0.732746,"eps":-0.023239,"divideRate":0,"volume":5382654,"delay":0,"ttmEps":-0.023239,"open":0.39,"prevYearClose":0.435,"prevWeekClose":0.395,"prevMonthClose":0.455,"prevQuarterClose":0.455,"fiveDayClose":0.37,"twentyDayClose":0.435,"sixtyDayClose":0.46},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527048658","title":"ASX Midday Sector Update: Healthcare Sector Jumps, Information Technology Stocks Struggle","url":"https://stock-news.laohu8.com/highlight/detail?id=2527048658","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527048658?lang=en_us&edition=fundamental","pubTime":"2025-04-15 11:36","pubTimestamp":1744688210,"startTime":"0","endTime":"0","summary":"The healthcare sector climbed 1.11% at midday Tuesday.Stocks rallied after some volatility on Wall Street, with investors cautiously optimistic after a temporary pause on tariffs on some electronic devices. The S&P 500 closed up 2.2%.Botanix Pharmaceuticals  received firm commitments to raise AU$40 million via a non-underwritten institutional placement, its shares rose 9% in midday trade.On the flip side, the information technology stocks fell, shedding 0.45%.EROAD  does not expect any material impact of the US' 10% blanket tariffs on its revenue or earnings, generating 44% of its revenue from the US market, with roughly 88% being from services not subject to the US import tariffs. It produces most of its hardware products through manufacturers in Indonesia, the Philippines, and Vietnam.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ERD.AU","HCSG","BK7084","BOT.AU","BK7139","BK4134","BK7508","III","BK7502","BK4137","BOQ.AU","BK7096"],"gpt_icon":0},{"id":"2527110765","title":"Botanix Pharmaceuticals Seeks AU$40 Million via Institutional Placement; Shares Rise 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527110765","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527110765?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:56","pubTimestamp":1744685780,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) received firm commitments to raise AU$40 million via a non-underwritten institutional placement, according to a Tuesday filing with the Australian bourse.The placemen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU","BK7502","BK7096","BK7508"],"gpt_icon":0},{"id":"2527778741","title":"BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2527778741","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527778741?lang=en_us&edition=fundamental","pubTime":"2025-04-15 09:24","pubTimestamp":1744680299,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Says Received Firm Commitments For A$40 Million April 15 (Reuters) - Botanix Pharmaceuticals BOT.AX:RECEIVED FIRM COMMITMENTS FOR A$40 MILLION CAPITAL RAISING AT ISSUE PRICE OF A$0.33 PER SHAREFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QS1Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2527120923","title":"Botanix Pharmaceuticals - Received Firm Commitments for a$40 Mln Capital Raising at Issue Price of a$0.33 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2527120923","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527120923?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:51","pubTimestamp":1744674712,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QS1Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BOT.AU","BK7502","BK7508"],"gpt_icon":0},{"id":"2527209261","title":"Botanix Pharmaceuticals Ltd-Proposed Issue of Securities - BOT","url":"https://stock-news.laohu8.com/highlight/detail?id=2527209261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527209261?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:51","pubTimestamp":1744674664,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nTUE4JFGYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7502","BK7508","BOT.AU"],"gpt_icon":0},{"id":"2527916812","title":"BRIEF-Botanix Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2527916812","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527916812?lang=en_us&edition=fundamental","pubTime":"2025-04-14 07:41","pubTimestamp":1744587700,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Seeks Trading HaltApril 14 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250413:nFWN3QQ05X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7502","BK7096","BOT.AU","BK7508"],"gpt_icon":0},{"id":"2524179651","title":"3 reasons to buy this surging ASX All Ords healthcare share today","url":"https://stock-news.laohu8.com/highlight/detail?id=2524179651","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524179651?lang=en_us&edition=fundamental","pubTime":"2025-04-02 08:16","pubTimestamp":1743553014,"startTime":"0","endTime":"0","summary":"On 11 March, the ASX All Ords healthcare share held a commercial update conference. The company reported that there are 10 million people in the US with axillary hyperhidrosis, with 3.7 million of those people currently seeking treatment. Botanix said it will focus on those patients seeking treatment with its targeted sales force. But the company also aims to capture some of the 6.3 million patients not actively seeking treatment via digital messaging. Botanix shares could also catch some tailwinds from the stock's 24 March addition to the S&P/ASX 300 Index . That came as part of the S&P Dow Jones Indices quarterly review and followed the big increase in the company's market cap over the prior year. With the ASX All Ords healthcare share now also an ASX 300 stock, it opens the door for more fund managers and index tracking funds to buy the stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/02/3-reasons-to-buy-this-surging-asx-all-ords-healthcare-share-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7502","XKO.AU","BK7508","BK7096","BOT.AU","XAO.AU"],"gpt_icon":0},{"id":"2522588479","title":"ASX Growth Stocks With High Insider Ownership That Stand Out","url":"https://stock-news.laohu8.com/highlight/detail?id=2522588479","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522588479?lang=en_us&edition=fundamental","pubTime":"2025-03-26 03:08","pubTimestamp":1742929687,"startTime":"0","endTime":"0","summary":"The Australian market has shown a mixed performance, with the ASX200 closing slightly up at 7,942 points, driven by gains in the IT and Health Care sectors. In this fluctuating environment, identifying growth companies with high insider ownership can be particularly appealing to investors seeking alignment between management and shareholder interests.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Overview: Accent Group Limited operates in the retail, distribution, and franchise sectors for lifestyle footwear, apparel, and accessories across Australia and New Zealand with a market cap of A$1.02 billion.Overview: Botanix Pharmaceuticals Limited is involved in the research and development of dermatology and antimicrobial products across Australia and the United States, with a market cap of A$867.17 million.Botanix Pharmaceuticals, recently added to the S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-stocks-high-insider-190807269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["TTT.AU","BK7021","BK7077","BK7508","BK7084","BBT.AU","FLT.AU","BK7158","BK7033","ACR.AU","BK7043","FND.AU","BK7078","AX1.AU","BK7116","XKO.AU","AAL.AU","XAO.AU","BK7096","CCA.AU","FEX.AU","AVA.AU","BK7093","BOT.AU","BK7070","NWF.AU","BK7036","PLT.AU","BK7129","XJO.AU","BK7502"],"gpt_icon":0},{"id":"2518763673","title":"ASX Market Close: Index pares losses as US recession fears rise | March 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518763673","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518763673?lang=en_us&edition=fundamental","pubTime":"2025-03-11 13:55","pubTimestamp":1741672500,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.9% at 7,890 points.It was a bloodbath today and IT was the worst performing sector, down 3.9%, followed by Industrials, down 2%, and Health Care, down 1.8%.Utilities was the best performing sector, up 1.4%, followed by Energy, up 0.76%.Botanix Pharmaceuticals  closed up 12.3% after posting a commercial update. The company says its sales team is performing on target, with a digital launch expected to add prescription volume.Vulcan Energy Resources  closed up 6.4% as energy stocks bucked the trend in a falling market.EZZ Life Sciences closed down 5.9% as the company flagged a strategic push to manufacture in the United States.Brickworksclosed down 6.9% after posting a non-cash impairment charge for its North American operations, citing challenging market conditions. The impairment is approximately AUD$55 million for the first half of 2025.Global asset managerGQG Partners closed down 3.2% afterreporting a 35.3% decline in net flow for February, as outflows from it","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-pares-losses-as-us-recession-fears-rise-march-11-2025-2025-03-11/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BKW.AU","BK7048","BOT.AU","BK7016","BK7504","BK7096","BK7503","BK7502","GQG.AU","EZZ.AU","BK7044","VGL.AU","BK7062","VUL.AU","BK7095","BK7508"],"gpt_icon":0},{"id":"2518739316","title":"BRIEF-Botanix Pharmaceuticals Announces Commercial Launch Of SOFDRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2518739316","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518739316?lang=en_us&edition=fundamental","pubTime":"2025-03-11 09:28","pubTimestamp":1741656514,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Announces Commercial Launch Of SOFDRAMarch 11 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX:ANNOUNCES COMMERCIAL LAUNCH OF SOFDRAFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PT124:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7502","BK7096","BK7508"],"gpt_icon":0},{"id":"2518843477","title":"Botanix Pharmaceuticals Says Commercial Launch of Lead Dermatology Product 'On Track'","url":"https://stock-news.laohu8.com/highlight/detail?id=2518843477","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518843477?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:31","pubTimestamp":1741645860,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said that the commercial launch of its lead dermatology product, Sofdra, a topical gel for treating excessive underarm sweating, remains \"on track,\" according to a Monday filing with the Australian bourse.The company's sales team is performing in line with expectations, and the full digital launch expected this month will further drive prescription volume, per the filing.Growth in new patient prescriptions is also on track, with refill rates exceeding targets, the filing added.The company also said it does not expect any material impact from tariffs on Sofdra.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7502","BK7096","BOT.AU","BK7508"],"gpt_icon":0},{"id":"2518926786","title":"Botanix Pharmaceuticals Ltd - Announces Commercial Launch of Sofdra","url":"https://stock-news.laohu8.com/highlight/detail?id=2518926786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518926786?lang=en_us&edition=fundamental","pubTime":"2025-03-11 05:23","pubTimestamp":1741641824,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT124:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","BK7096","BOT.AU","BK7508"],"gpt_icon":0},{"id":"2517149771","title":"Analysts Are Optimistic We'll See A Profit From Botanix Pharmaceuticals Limited (ASX:BOT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517149771","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517149771?lang=en_us&edition=fundamental","pubTime":"2025-03-07 09:42","pubTimestamp":1741311761,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Limited  is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. The company’s loss has recently broadened since it announced a AU$14m loss in the full financial year, compared to the latest trailing-twelve-month loss of AU$39m, moving it further away from breakeven. As path to profitability is the topic on Botanix Pharmaceuticals' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.Botanix Pharmaceuticals is bordering on breakeven, according to some Australian Pharmaceuticals analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of AU$3.7m in 2025. Therefore, the company is expected to breakeven roughly 12 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysts-optimistic-well-see-profit-014241738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BOT.AU","BK7508","BK7502","BK7096"],"gpt_icon":0},{"id":"2517111504","title":"Botanix Pharmaceuticals Stock Sell-Off Has 'No Good Reasons,' Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2517111504","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517111504?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:46","pubTimestamp":1741297596,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals'  stock slump is backed by no \"good\" company-specific reason aside from broader macroeconomic factors, said Euroz Hartleys in a Thursday note.The stock has seen continuous sessions of losses since it reported a wider fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.The research firm believes the company's half-year results were unsurprising, and the extent of the stock's decline remains \"puzzling.\"The company will see a negligible financial impact from the newly imposed 25% tariff on Canadian exports, the note added.The research firm maintained its buy rating and price target of AU$0.55 on Botanix Pharmaceuticals.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7502","BK7096","BOT.AU","BK7508"],"gpt_icon":0},{"id":"2514089483","title":"Botanix Pharmaceuticals Posts Wider Fiscal H1 Loss, Lower Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514089483","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514089483?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:21","pubTimestamp":1740612075,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  reported Wednesday a fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.Revenue for the six months ended Dec. 31, 2024, was AU$345.7 million, compared with AU$377.9 million a year earlier.The company's shares fell 1% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU"],"gpt_icon":0},{"id":"2514022197","title":"BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$30.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514022197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514022197?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:33","pubTimestamp":1740533632,"startTime":"0","endTime":"0","summary":"BRIEF-Botanix Pharmaceuticals Posts HY Loss Attributable A$30.9 MlnFeb 26 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX:HY LOSS ATTRIBUTABLE A$30.9 MILLIONFurther company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG12X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","BK7502","BOT.AU"],"gpt_icon":0},{"id":"2510828552","title":"Analysts Are Optimistic We'll See A Profit From Botanix Pharmaceuticals Limited (ASX:BOT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510828552","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510828552?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:47","pubTimestamp":1739227673,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Botanix Pharmaceuticals...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/analysts-are-optimistic-well-see-a-profit-from-botanix-pharm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7096","BK7502","BOT.AU"],"gpt_icon":0},{"id":"2510886743","title":"Sales Traction from Botanix Pharmaceuticals' Prescription Gel Launch May Drive Stock Re-rating, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2510886743","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510886743?lang=en_us&edition=fundamental","pubTime":"2025-02-10 14:52","pubTimestamp":1739170370,"startTime":"0","endTime":"0","summary":"Sales traction from Botanix Pharmaceuticals'  full commercial launch of Sofdra, its prescription treatment for excessive underarm sweating, could lead to a potential stock rating above its price target, according to a Monday note by Euroz Harlteys.On Jan. 31, the company said that the full commercial launch of Sofdra is officially underway, with sales professionals set to hit the field within the next week.Early patient feedback from social media and online sources shows that Sofdra is effective compared to its alternatives, with minimal side effects, with patients receiving full insurance coverage, Euroz said.The feedback is positive for BOT and raises Euroz's confidence in the company's ongoing commercial rollout.Euroz maintained Botanix Pharmaceuticals' buy rating and its AU$0.55 price target.Shares of the company rose 7% at market close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU"],"gpt_icon":0},{"id":"2509424162","title":"Botanix Pharmaceuticals' Prescription Gel Commercial Launch Could Drive Stock Re-rating, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2509424162","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509424162?lang=en_us&edition=fundamental","pubTime":"2025-02-05 14:41","pubTimestamp":1738737683,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  is poised for a significant stock re-rating as it nears the full commercial launch of Sofdra, a prescription treatment for excessive underarm sweating, according to a Tuesday note by Euroz Harlteys.Euroz Hartleys expects sales from the launch to push the stock above Botanix Pharmaceuticals' price target.On Jan. 31, the company said that the full commercial launch of Sofdra is officially underway, with sales professionals set to hit the field within the next week.Botanix Pharmaceuticals also said a digital launch of Sofdra is scheduled for the quarter.Euroz noted that the company has completed agreements with all major health insurers in the US to ensure that Sofdra, will be covered under the insurers' plans.The agreements will make Sofdra accessible to 167 million people who are covered by these insurers, Euroz added.The company has also met the criteria for US government health programs, granting Sofdra access to an additional 80 million people starting in Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU"],"gpt_icon":0},{"id":"2500680904","title":"5 ASX All Ords shares starting the new year at 52-week highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2500680904","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500680904?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:00","pubTimestamp":1735851600,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords Index  shares closed higher on the first day of trading for 2025.The ASX All Ords finished 0.53% higher at 8,465 points on Thursday.Here are five ASX All Ords shares that started the new year on a positive note with 52-week high prices.5 ASX All Ords shares that hit 52-week highs on Thursday. It's rather fitting that the No. 1 stock among the 5 best-performing ASX All Ords stocks of 2024 started the new year at a four-year high.The Mesoblast share price reached $3.37 in intraday trading on Thursday.However, the ASX All Ords stock has been on an upward trajectory since the biotech gained approval from the United States Food and Drug Administration for its lead drug, remestemcel-L, last month.Branded Ryoncil, the drug is the first approved treatment for steroid-refractory acute graft versus host disease  in children and the first mesenchymal stromal cell  therapy approved in the US.Another ASXAll Ords techshare, Bravura Solutions, also clocked a 52-week high yesterday.AS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/5-asx-all-ords-shares-starting-the-new-year-on-52-week-highs/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4150","BK7061","BK7503","APX.AU","BK7502","BK7508","MSC","PRN.AU","BVS.AU","BK7095","BOT.AU","BK7501","XAO.AU","BK7067","BK4575","MSB.AU","BK7016","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[]}}